[1] |
SONG Yan, GAO Linyan, ZHANG Yanping, LI Xiang, ZHANG Lan.
Application of medical failure mode and effect analysis in blood sample management in phase I clinical trials#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1031-1036.
|
[2] |
ZHONG Zihang, CHEN Feng, YUAN Ying, CHENG Jiancheng, YU Xuanxuan, YANG Min, TAN Mingmin, ZHAO Yang, BAI Jianling, YU Hao.
A novel model-assisted design in phase I clinical trials: Bayesian optimal interval design
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 640-648.
|
[3] |
YANG Haijing, YU Jicheng, WANG Jingjing, LI Nanyang, WU Jufang, ZHANG Hai, XUE Tao, DAI Weiguo, DING Tianling, CAO Guoying.
Risk management of biological agents in phase I clinical trials: Case sharing
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 44-48.
|
[4] |
CAO Bei, GENG Yan, LI Juan.
Brief probe into the application of BEIS system of ECRFPlus in Phase I clinical trials
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1431-1437.
|
[5] |
YE Yujie, YUAN Weian, HE Min.
Implementation points of the urine sample collection in phase I clinical trial of drugs
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1438-1440.
|
[6] |
HUANG Ping, ZUO Rong, XIA Chun-hua, XIONG Yu-qing.
Brief introduction to phase I clinical trial subjects management
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 320-322.
|
[7] |
LU Yan, LI Tao, JIA Zeng-qin, GAO Rui, TANG Xu-dong.
Experience about causality assessment of fibrinogen in phase I clinical trial of Chinese herbal medicine
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(1): 55-58.
|
[8] |
WANG Xiu-Qin, XIONG Ning-Ning, LIU Shen-Lin, LI Qi-Yi, JIANG Meng, LIU Fang, ZOU Jian-Dong, XUE Jun, BO Qing-Yan, GAO Wei-Min.
Ethic Review in Clinical Research: Subjects Recruitment
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(11): 1313-1316.
|